Advertisement
The press release and a live audio-only Webcast of the conference call canbe accessed through a link that is posted on the home page and InvestorRelations section of the Nektar website: http://www.nektar.com. The webbroadcast of the conference call will be available for replay throughWednesday, August 20, 2008.
Advertisement
An audio replay will also be available shortly following the call throughWednesday, August 20, 2008 and can be accessed by dialing (888) 286-8010(U.S.); or (617) 801-6888 (international) with a passcode of 67859021.
In the event that any non-GAAP financial measure is discussed on theconference call that is not described in the press release, relatedinformation will be made available on the Investor Relations page at theNektar website as soon as practical after the conclusion of the conferencecall.
About Nektar
Nektar Therapeutics is a biopharmaceutical company that develops andenables differentiated therapeutics with its industry-leading PEGylation andpulmonary drug development platforms. Nektar's technology and drug developmentexpertise have enabled nine approved products for partners, which includeleading biopharmaceutical companies. Nektar is also developing a robustpipeline of its own high-value therapeutics that addresses unmet medical needsby leveraging and expanding its technology platforms to improve and enablemolecules.To access the conference call, follow these instructions: Dial: (866) 831-5605 (U.S.); (617) 213-8851 (international) Passcode: 33430853 (Howard Robin is the host)
SOURCE Nektar Therapeutics
